Clinical experience of linezolid in bone marrow transplantation patients

Journal of Pharmacy Practice

Volumn 23, Issue 4, 2010, Pages 352-357

  Hogan, Holly L ^a   Hachem, Ray Y ^a   Neuhauser, Melinda ^a   Raad, Issam I ^a   Coyle, Elizabeth ^a  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

bone marrow transplantation; engraftment; linezolid; neutropenia; thrombocytopenia

Indexed keywords

COLONY STIMULATING FACTOR; ERYTHROPOIETIN; LINEZOLID; STEROID; VANCOMYCIN;

ADULT; ANTIBIOTIC THERAPY; ARTICLE; BLEEDING; BONE MARROW TRANSPLANTATION; CANCER CHEMOTHERAPY; CLINICAL ARTICLE; CONTROLLED STUDY; DISEASE CLASSIFICATION; DISEASE SEVERITY; DRUG SAFETY; ENGRAFTMENT; ERYTHROCYTE TRANSFUSION; FEMALE; HOSPITAL PATIENT; HOSPITALIZATION; HUMAN; LEUKOCYTE TRANSFUSION; MALE; NEUTROPENIA; RETROSPECTIVE STUDY; RISK ASSESSMENT; SURGICAL PATIENT; THROMBOCYTE COUNT; THROMBOCYTE TRANSFUSION; THROMBOCYTOPENIA; TREATMENT DURATION;

EID: 77956253618     PISSN: 08971900     EISSN: 15311937     Source Type: Journal    
DOI: 10.1177/0897190009358773     Document Type: Article

References (18)

1. Hughes WT, Armstrong D., Bodey GP, et al. Guidelines for the use of antimicrobial agents in neutropenic patients with cancer. Clin Infect Dis. 2002 ; 34 (6). 730-751.
2. Cordonnier C., Buzyn A., Leverger G., et al. Epidemiology and risk factors for Gram-positive coccal infections in neutropenia: toward a more targeted antibiotic strategy. Clin Infect Dis. 2003 ; 36 (2). 149-158.
3. Zyvox [package insert]. Kalamazoo, MI: Pharmacia & Upjohn Company ; 2002.
4. Abb J. In vitro activity of linezolid, quinupristin-dalfopristin, vancomycin, teicoplanin, moxifloxacin and mupirocin against methicillin- resistant Staphylococcus aureus: comparative evaluation by the Etest and a broth microdilution. Diagn Microbiol Infect Dis. 2002 ; 43 (4). 319-321.
5. Noskin GA, Siddiqui F., Stosor V., et al. In vitro activities of linezolid against important gram-positive bacterial pathogens vancomycin-resistant enterococci. Antimicrob Agents Chemother. 1999 ; 43 (8). 2059-2062.
6. Cercenado E., Garcia-Garrote F., Bouza E. In vitro activity of linezolid against multiply resistant gram-positive clinical isolates. J Antimicrob Chemother. 2001 ; 47 (1). 77-81.
7. Shinabarger DL, Marotti KR, Murray RW, et al. Mechanism of action of oxazolidinones: effects of linezolid and eperezolid on translation reactions. Antimicrob Agents Chemother. 1997 ; 41 (10). 2132-2136.
8. Attassi K., Hershberger E., Alam R., et al. Thrombocytopenia associated with linezolid therapy. Clin Infect Dis. 2002 ; 34 (5). 695-698.
9. Orrick JJ, Johns T., Janelle J., et al. Thrombocytopenia secondary to linezolid administration: what is the risk ? Clin Infect Dis. 2002 ; 35 (3). 348-349.
10. Halpern M. Linezolid-induced pancytopenia. Clin Infect Dis. 2002 ; 35 (3). 347-348.
11. Green SL, Maddox JC, Huttenbach ED Linezolid and reversible myelosuppression. JAMA. 2001 ; 285 (10). 1291.
12. Waldrep TW, Skiest DJ Linezolid-induced anemia and thrombocytopenia. Pharmacotherapy. 2002 ; 22 (1). 109-112.
13. Gerson SL, Kaplan SL, Bruss JB, et al. Haematological effects of linezolid: summary of clinical experience. Antimicrob Agents Chemother. 2002 ; 46 (8). 2723-2726.
14. Jaksic B., Martinelli G., Perez-Oteyza J., et al. Efficacy and safety of linezolid compared with vancomycin in a randomized, double-blind study of febrile neutropenic patients with cancer. Clin Infect Dis. 2006 ; 42 (5). 597-607.
15. Grau S., Morales-Molina JA, Mateu-de Antonio J., et al. Linezolid: low pre-treatment platelet values could increase the risk of thrombocytopenia. J Antimicrob Chemother. 2005 ; 56 (2). 440-441.
16. Senneville E., Legout L., Valette M., et al. Risk factors for anaemia in patients on prolonged linezolid therapy for chronic osteomyelitis: a case-control study. J Antimicrob Chemother. 2004 ; 54 (4). 798-802.
17. Rao N., Ziran BH, Wagener MM, et al. Similar hematological effects of long-term linezolid and vancomycin therapy in a prospective observational study of patients with orthopedic infections. Clin Infect Dis. 2004 ; 38 (8). 1058-1064.
18. Davies SM, Kollman C., Anasetti C., et al. Engraftment and survival after unrelated-donor bone marrow transplantation: a report from the national marrow donor program. Blood. 2000 ; 96 (13). 4096-4102.